Crystal Research Associates has issued a 16-page Company Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).
Snapshot of GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing next-generation vaccines and immunotherapies for serious infectious diseases and solid tumors. Its lead infectious disease candidate, GEO-CM04S1, is a multi-antigen COVID-19 vaccine designed to provide broader, longer-lasting protection, especially for immunocompromised individuals. Currently in three Phase 2 trials, GEO-CM04S1 is being studied in healthy adults, patients with Chronic Lymphocytic Leukemia (CLL), and individuals undergoing stem cell transplant or CAR-T therapy. In oncology, GeoVax is preparing a new Phase 2 trial of Gedeptin® as a neoadjuvant therapy for head and neck squamous cell carcinoma, in combination with pembrolizumab and fludarabine. Additional preclinical studies are ongoing in other tumor types. The Company’s Mpox and smallpox vaccine candidate, GEO-MVA, is expected to enter clinical trials in late 2025, following favorable guidance from the European Medicines Agency supporting a streamlined development path. Backed by global rights, a growing intellectual property portfolio, and scalable manufacturing capabilities—including a transition to cell-based platforms—GeoVax is led by an experienced management team focused on advancing high-impact vaccines and immunotherapies to address urgent and underserved medical needs.
Key Points
- On July 28, 2025, GeoVax reported a net loss of $5.4 million ($0.35 per share) for Q2 2025, compared to a net loss of $5.1 million ($1.99 per share) in Q2 2024.
- Key pipeline programs advanced during the quarter, including favorable European Medicines Agency (EMA) guidance for GEO-MVA and strong immune response data from GEO-CM04S1 in immunocompromised patients, particularly those with Chronic Lymphocytic Leukemia (CLL).
- GEO-MVA is now positioned for centralized EU approval and global procurement access. As the only U.S.-based MVA vaccine developer for Mpox/smallpox, GeoVax is targeting a $10 billion+ market amid rising demand and transitioning to scalable, cell-based manufacturing.
- Preparations are underway for a Phase 2 trial of Gedeptin® in head and neck cancer, reinforcing GeoVax’s focus on immunotherapies for underserved oncology indications.
- During the quarter, Dr. Senthil Ranganathan joined as VP of Technical Development and CMC Operations, bringing 20+ years of biologics and manufacturing expertise across vaccines, viral vectors, and cell and gene therapies.
- GeoVax further strengthened its IP portfolio with a new U.S. patent covering its malaria vaccine platform and a Notice of Allowance for claims related to Gedeptin® combined with radiation therapy. The Company now holds over 135 patents across 23 families, supporting its multi-antigenic approach to infectious disease and cancer.
- GeoVax ended Q2 with $3.1 million in cash and completed a public offering in July 2025, raising $5.6 million in net proceeds to support operations and near-term growth.
*******************************************
Visit our Corporate Profile and Key Points pages
for the latest research on GeoVax Labs, Inc.
*******************************************